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Encapsulating peritoneal sclerosis is a complication of
peritoneal dialysis characterized by persistent, intermittent,
or recurrent adhesive bowel obstruction. Here we examined
the incidence, predictors, and outcomes of encapsulating
peritoneal sclerosis (peritoneal fibrosis) by multivariate
logistic regression in incident peritoneal dialysis patients in
Australia and New Zealand. Matched case–control analysis
compared the survival of patients with controls equivalent
for age, gender, diabetes, and time on peritoneal dialysis.
Of 7618 patients measured over a 13-year period,
encapsulating peritoneal sclerosis was diagnosed in 33,
giving an incidence rate of 1.8/1000 patient-years. The
respective cumulative incidences of peritoneal sclerosis at
3, 5, and 8 years were 0.3, 0.8, and 3.9%. This condition was
independently predicted by younger age and the duration of
peritoneal dialysis, but not the rate of peritonitis. Twenty-six
patients were diagnosed while still on peritoneal dialysis.
Median survival following diagnosis was 4 years and not
statistically different from that of 132 matched controls.
Of the 18 patients who died, only 7 were attributed directly
to peritoneal sclerosis. Our study shows that encapsulating
peritoneal sclerosis is a rare condition, predicted by younger
age and the duration of peritoneal dialysis. The risk of
death is relatively low and not appreciably different from
that of competing risks for mortality in matched dialysis
control patients.
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Encapsulating peritoneal sclerosis (EPS), also known as
peritoneal fibrosis, peritoneal sclerosis, sclerosing obstructive
peritonitis, sclerosing encapsulating peritonitis, calcific perito-
nitis, abdominal cocoon, and sclerosing peritonitis,1–5 is a rare
complication of peritoneal dialysis (PD) therapy characterized
by persistent, intermittent, or recurrent adhesive bowel
obstruction with features of encapsulation due to peritoneal
fibrosis.6 Its clinical manifestations are variable,1,2,6–11 there are
no reliable biochemical or radiological screening tests,6,12–14
and diagnosis is often delayed until after cessation of PD in up
to 74% of cases.11 The reported incidence of EPS varies from
0.3 to 3.3%.1,11,15–19 There is no known single etiologic factor
directly related to EPS,1,16,20 although PD duration has been
identified as a risk factor.11,16,17,20,21 The observed risk of EPS
after 5 years of PD has been reported to vary from 2.1% in
Japan17 to 6.4% in Australia16 and to 8.1% in Scotland.11 Other
factors that have variably been associated with EPS risk include
bioincompatible dialysate,8,22,23 icodextrin,24,25 chlorhexidine
disinfectant,26 povidone-iodine,27 dialysate contamination with
plasticizers and particulate matter,1,23,27 PD catheters,28
b-blockers,7,29 and severe peritonitis.1,16,22 It is generally accepted
that PD should be discontinued after diagnosis of EPS.
Isolated case reports and relatively small cases series suggest
additional potential therapeutic roles for peritoneal lavage,30
nutritional support,21 corticosteroids,17,31 tamoxifen,19,21,32
immunosuppression,16,33–36 and enterolysis.37–40 Reported
mortality rates vary between 25.8 and 56.5%.1,11,15–19
In a recent position paper published by the International
Society for PD,20 the EPS guidelines work group indicated
that issuing clear evidence-based guidelines on EPS was
greatly hampered by lack of epidemiologic data in different
dialysis populations relating length of time on PD with the
odds of developing EPS, lack of well-defined diagnostic
criteria (especially in the early stages of EPS), development or
progression of EPS after PD discontinuation, and lack of
satisfactory intervention and outcome data. Previous EPS
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studies have been potentially limited by small numbers,
retrospective study designs (raising the possibility of recall
bias), variable EPS diagnostic criteria, use of outdated data,
inclusion of prevalent patients (thereby making incidence
calculation difficult and raising the possibility of Neyman
bias), and lack of case–control analysis to ascertain EPS
outcomes.
The aim of this study was to examine the incidence,
predictors, and clinical outcomes of EPS in incident PD
patients in Australia and New Zealand. A secondary aim was
to compare the survival of patients developing EPS with that
of controls matched for age, gender, presence or absence of
diabetes mellitus, and time on PD.
RESULTS
Incidence of EPS
A total of 7618 patients commenced PD in Australia and
New Zealand during the study period (1 January 1995 to
31 December 2007). The total study follow-up was 31,555
patient-years, of which 18,798 patient-years involved PD
treatment. Median PD technique survival, censored for
kidney transplantation and spontaneous recovery of renal
function, was 2.4 years (95% confidence interval (CI) 2.3–2.4
years). Median overall patient survival was 4.6 years (95% CI
4.4–4.7 years).
During the study, 33 (0.4%) patients were diagnosed with
EPS over a median PD duration of 4.5 (interquartile range
2.2–6.1) years. The characteristics of patients who did and did
not experience EPS are shown in Table 1. The incidence rate
of EPS was 1.8 per 1000 patient-years of PD (95% CI
1.2–2.5). The cumulative hazard of developing EPS after
commencing PD is shown in Figure 1. Compared with
patients who received PD foro4 years, the odds ratios (ORs)
of developing EPS were 4.89 (95% CI 2.38–10.6) for patients
receiving PD for 4–8 years and 12.1 (95% CI 3.44–42.3) for
patients receiving PD for 48 years.
A total of 26 (79%) patients were on PD at the time of EPS
diagnosis. All were transferred to hemodialysis immediately
after diagnosis. In the remaining seven (21%) patients, EPS
was diagnosed after a median period of 0.75 years (inter-
quartile range 0.54–1.01 years) after transfer from PD to
hemodialysis. The recorded indications for transfer to
hemodialysis in these seven patients were acute peritonitis
(n¼ 2), impaired small solute clearance (n¼ 1), impaired
ultrafiltration (n¼ 1), abdominal surgery (n¼ 1), inability to
manage self-care (n¼ 1), and medical decision (n¼ 1). No
patients had EPS diagnosed after renal transplantation,
although three (9%) patients with EPS subsequently under-
went renal transplantation.
Predictors of EPS
On univariate analysis, patients who experienced EPS during
the study period were more likely to be younger, current
smokers, commenced dialysis in an earlier era, have longer
follow-up times, and spend a longer period on PD than
patients who did not develop EPS. On multivariate binary
logistic regression analysis, the diagnosis of EPS was
significantly and independently predicted by younger age
(adjusted OR per decade 0.81, 95% CI 0.66–0.98, P¼ 0.03)
and total years spent on PD (OR 1.34, 95% CI 1.17–1.53).
The other covariates remaining in the final model (initial
dialysis modality, dialysis vintage, and chronic lung disease)
were not significantly associated with EPS risk. When age was
considered as a categorical variable according to tertiles
(o53.4, 53.4–67.5, and 467.5 years), the diagnosis of EPS
was significantly predicted by the youngest tertile of age
(youngest tertile OR 4.87, 95% CI 1.44–16.5; middle tertile
OR 2.51, 95% CI 0.68–9.32; oldest tertile reference) and total
years spent on PD (OR 1.32, 95% CI 1.15–1.51). There was
no significant interaction observed between age and time
spent on PD. The development of EPS was not associated
with gender, racial origin, body mass index, late referral,
smoking status, chronic lung disease, coronary artery disease,
peripheral vascular disease, cerebrovascular disease, diabetes
mellitus, end-stage renal disease cause, center size, state
where treated, dialysis era, first renal replacement therapy for
end-stage renal disease, proportion of PD time spent on
automated PD, or peritonitis frequency (episodes per
patient-year).
When only baseline predictors were considered in the
logistic regression analysis (that is, by dropping total time on
PD, proportion of time on PD, and peritonitis frequency
from the model), younger age became the sole independent
predictor of EPS (youngest tertile OR 5.36, 95% CI 1.59–18.1;
middle tertile OR 2.77, 95% CI 0.75–10.3, oldest tertile
reference). Using multivariate Cox’s proportional hazards
model analysis, time to EPS development on PD was signi-
ficantly predicted by the youngest tertile of age (youngest
tertile OR 5.24, 95% CI 1.36–20.2; middle tertile OR 2.44,
95% CI 0.62–10.9, oldest tertile reference). There were no
other independent predictors of time to EPS onset.
Outcomes of EPS
A total of 18 (55%) patients with EPS died during the study.
This equated to 20 deaths per 100 patient-years after EPS
diagnosis. The recorded causes of death are shown in Table 2.
Eight (24%) patients died within 1 week of the recorded date
of EPS diagnosis, of which four were directly attributed to
EPS. The remaining three deaths that were directly attributed
to EPS occurred at 0.6, 4.1, and 4.8 years after diagnosis.
Overall survival rates for patients with EPS at 1, 2, 3, and
5 years after diagnosis were 69, 62, 58, and 35%, respectively.
The median survival after diagnosis of EPS was 4.0 years
(95% CI 1.8–6.3 years; Figure 2).
The median time from commencement of PD to death in
patients who developed EPS was 8.6 years (95% CI 3.4–13.7
years), which was significantly longer than that observed in
patients who did not develop EPS (4.6 years, 95% CI 4.4–4.7
years). In an attempt to minimize the effect of survivor bias
on survival comparisons (due to the fact that the patients
who developed EPS had to survive a considerable number of
years on PD before EPS diagnosis), a matched case–control
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Table 1 | Characteristics of all incident PD patients in Australia and New Zealand who did and did not experience EPS during
the period 1995–2007
Characteristic EPS (n=33) No EPS (n=7585) P-value
Age (years) 49.1±12.8 58.0±16.6 0.002
Women 16 (49%) 3535 (47%) 0.8
Racial origin 0.1
Caucasian 18 (55%) 5055 (67%)
ATSI 1 (3%) 585 (8%)
MPI 8 (24%) 1241 (16%)
Asian 3 (9%) 472 (6%)
Other 3 (9%) 232 (3%)
BMI (kg/m2) 25.8±6.3 26.2±5.5 0.7
eGFR at dialysis start (ml/min per 1.73m2) 5.3±1.4 (available n=18) 7.4±6.8 (available n=6077) 0.2
Late referral 11 (33%) 1765 (23%) 0.2
ESRF cause 0.4
Chronic glomerulonephritis 12 (36%) 1985 (26%)
Diabetic nephropathy 10 (30%) 2533 (33%)
Renovascular disease 1 (3%) 967 (13%)
Polycystic kidneys 0 (0%) 350 (5%)
Reflux nephropathy 2 (6%) 261 (3%)
Other 6 (18%) 1031 (13%)
Unknown 2 (6%) 458 (6%)
Current smoker 7 (21%) 1058 (14%) 0.02
Chronic lung disease 0 (0%) 1118 (15%) 0.02
Coronary artery disease 11 (33%) 2996 (40%) 0.5
Peripheral vascular disease 4 (12%) 2002 (26%) 0.06
Cerebrovascular disease 3 (9%) 1164 (15%) 0.3
Diabetes mellitus 13 (39%) 3115 (41%) 0.8
First RRT 0.2
HD 19 (58%) 3123 (41%)
PD 14 (42%) 4437 (59%)
Kidney transplant 0 (0%) 25 (0%)
Dialysis era o0.002
1995–1997 15 (46%) 1830 (24%)
1998–2000 9 (27%) 1905 (25%)
2001–2003 9 (27%) 1938 (26%)
2004–2007 0 (0%) 1912 (25%)
Prescribed dialysate volume at baseline (l/week) 56 (56–63)a 56 (56–70)a 0.09
Centre size (no. of PD patients) 0.7
Small (p10) 0 (0%) 76 (1%)
Small-Med (11–38) 3 (9%) 528 (7%)
Med-Large (39–98) 5 (15%) 1687 (22%)
Large (X99) 25 (76%) 5294 (70%)
State 0.8
New South Wales 10 (30%) 2203 (29%)
Northern Territory 0 (0%) 128 (2%)
Queensland 2 (6%) 1070 (14%)
South Australia 1 (3%) 257 (3%)
Tasmania 0 (0%) 98 (1%)
Victoria 6 (18%) 1075 (14%)
Western Australia 2 (6%) 638 (8%)
New Zealand 12 (36%) 2116 (28%)
Peritonitis (episodes/patient-year) 0.8 (0.4–1.2)a 1.1 (0.6–2.1)a 0.04
Total follow-up time (years) 6.7 (4.2–10.3)a 3.4 (1.8–5.8)a o0.001
Total years on PD 4.5 (2.2–6.1)a 2.0 (1.1–3.4)a o0.001
Proportion of time on APD 0 (0–0.33)a 0 (0–0.51)a 0.9
Abbreviations: APD, automated peritoneal dialysis; ATSI, Aboriginal and Torres Strait Islander; BMI, body mass index; eGFR, estimated glomerular filtration rate; EPS,
encapsulating peritoneal sclerosis; ESRF, end-stage renal failure; HD, hemodialysis; MPI, Maori and Pacific Islander; RRT, renal replacement therapy.
aInterquartile range.
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analysis was performed. For each EPS case, four control PD
patients were selected, matched for age, gender, diabetes
mellitus, and time spent on PD. The baseline characteristics
of the EPS cases and controls were well matched, except that
EPS cases were significantly less likely to have chronic lung
disease (OR 1.29, 95% CI 1.18–1.41; Table 3). No significant
differences were observed in survival between EPS cases and
controls (log rank score 0.004, P¼ 0.9; Figure 3). The causes
of death in the matched controls were cardiovascular (32 or
53%), dialysis withdrawal (15 or 25%), infection (8 or 13%),
bowel infarction (2 or 3%), cachexia (2 or 3%), and dialysis
access hemorrhage (1 or 2%).
DISCUSSION
This study represents the largest PD population study to date,
in which the incidence, predictors, and outcomes of EPS have
been examined. The occurrence rate of EPS in our study
(0.4%) was somewhat lower than what has been previously
reported in large, multi-center studies in the United King-
dom (2.8–3.3%),11,19 Japan (0.8–2.5%),15,17,18 and Korea
(0.8%).1 Part of the apparent disparity may be explained by
the fact that many of the other studies may have over-
estimated incidence rates because of the inclusion of
prevalent PD patients and the expression of results per total
number of patients rather than per patient-years at risk.
Another possibility is that patients in our study spent a
considerably shorter period of time on PD compared with
those in other studies as a result of relatively higher
peritonitis and technique failure rates, thereby potentially
minimizing their exposure risk for EPS. The median
technique survival in the Australian and New Zealand PD
patient populations was 2.4 years, such that only 10 and 1.4%
of patients completed 5 and 8 years of PD therapy,
respectively. These technique survival rates are considerably
lower than those reported by many countries in Asia,
Europe, and North and South America (reviewed in
Nakamoto et al.41), but comparable to those reported in
the United Kingdom.42 Interestingly, the occurrence rate of
EPS in our study (0.4%) was similar to that reported by
Rigby et al.16 in Australia between 1980 and 1989 (0.4%), but
lower than that reported between 1990 and 1994 (1.0%). The
apparent disparity may be at least partly explained by an
increase in median technique survival from approximately
2.5 years in 1980 to over 3 years between 1990 and 1994,43
followed by a subsequent decrease to 2.4 years in the most
recent cohort.
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Figure 1 |Cumulative hazard for developing encapsulating peritoneal sclerosis (EPS) in incident peritoneal dialysis (PD) patients in
Australia and New Zealand in 1995–2007.
Table 2 | Causes of death in patients diagnosed with EPS in
Australia and New Zealand in 1995–2007
Cause Number (%)
EPS 7 (39%)
Cardiovascular disease 4 (22%)
Cerebrovascular disease 2 (11%)
Pneumonia 1 (6%)
Vascular access infection 1 (6%)
Vascular access hemorrhage 1 (6%)
Malignancy 1 (6%)
Hepatic failure 1 (6%)
Total 18 (100%)
Abbreviation: EPS, encapsulating peritoneal sclerosis.
A total of 15 patients were still alive at the end of the study.
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The strong, independent association between PD duration
and EPS risk in our study supports the findings of previous
investigations.11,16,17,20,21 As with other studies, EPS was
exceedingly rare in the first 3 years of PD therapy and was
observed with increasing frequency thereafter. Nevertheless,
the cumulative incidences of EPS in our study at 5 years
(0.8%) and 8 years (3.9%) were somewhat lower than those
reported in the United Kingdom (2.0 and 8.1%, respectively),
but higher than those observed in Japan (0.7 and 2.1%,
respectively).
A novel aspect of our study was the comparison of
incident PD patients who did and did not develop EPS with
respect to a large number of demographic and clinical
parameters to identify independent predictors of EPS. Using
multivariate analysis, the only two independent predictors of
EPS development were longer time spent on PD and younger
age. The effect of patient age on EPS development has not
been previously studied, although Kawanishi et al.17 observed
that the average patient age at EPS diagnosis was 3 years
younger than that of all patients at PD termination, whereas
Yamamoto et al.44 reported that the average age of 12 patients
with EPS (35.1±3.3 years) was appreciably lower than that of
128 patients who did not develop EPS (47.3±1.1 years). In
this study, patients developing EPS were significantly younger
(by 8.9 years) at PD onset than patients who did not develop
EPS and had fewer comorbid illnesses. The greatest risk
of developing EPS was in the youngest tertile of patients
(o53.4 years). However, it is important to emphasize that
both our group45 and others46,47 have shown that young
individuals without comorbid illness also represent the group
of end-stage kidney disease patients who are most likely to
derive a survival benefit with PD relative to hemodialysis, at
least within the first 3–4 years. This benefit exceeds the small
risk of developing EPS.
Interestingly, despite previous reports of PD-associated
peritonitis as a risk factor for EPS development,1,16,22 we were
not able to show a relationship between peritonitis frequency
and EPS risk. Indeed, peritonitis frequency tended to be
lower in patients who developed EPS, although this may
represent bias by indication, as patients with less frequent
peritonitis are likely to remain on PD longer and therefore
have a greater EPS exposure risk.
Another novel aspect of this study was the evaluation of
survival of patients with EPS compared with that of PD
controls matched for age, gender, presence or absence of
diabetes mellitus, and time spent on PD. After the diagnosis
of EPS, patients who survived for a median period of 4 years
and their overall survival from the commencement of PD was
not significantly different from that of matched controls. The
majority (61%) of deaths were not attributed to EPS per se.
These results suggest that a diagnosis of EPS may still be
compatible with reasonable periods of survival and that the
risk of death is not appreciably greater than that from
competing risks for mortality in dialysis patients (for
example, infectious and cardiovascular mortality). Direct
comparison of EPS patient survival with that of other studies
is difficult because most have quoted mortality rates of
between 25.8 and 56.5% over variable study follow-up
periods.1,11,15–19 In the Pan-Thames EPS study, Balasubramaniam
et al.21 reported a 1-year overall survival of 56% with a median
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Figure 2 |Kaplan–Meier survival curve for all patients diagnosed with encapsulating peritoneal sclerosis (EPS) in Australia and
New Zealand in 1995–2007.
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Table 3 | Characteristics of EPS cases compared with matched controls
Characteristic EPS cases (n=33) Controls (n=132) P-value
Age (years) 49.1±12.8 48.7±13.0 0.9
Women 16 (49%) 64 (49%) 1.0
Diabetes mellitus 13 (39%) 51 (39%) 0.9
Time spent on PD (years) 4.5 (2.2–6.1)a 4.5 (2.4–6.1)a 0.9
Racial origin 0.9
Caucasian 18 (55%) 75 (57%)
ATSI 1 (3%) 8 (6%)
MPI 8 (24%) 26 (20%)
Asian 3 (9%) 12 (9%)
Other 3 (9%) 11 (8%)
BMI (kg/m2) 25.8±6.3 25.5±5.5 0.8
eGFR at dialysis start (ml/min per 1.73m2) 5.3±1.4 6.2±3.1 0.2
Late referral 11 (33%) 36 (27%) 0.5
ESRF cause 0.9
Chronic glomerulonephritis 12 (36%) 47 (36%)
Diabetic nephropathy 10 (30%) 42 (32%)
Renovascular disease 1 (3%) 7 (5%)
Polycystic kidneys 0 (0%) 5 (4%)
Reflux nephropathy 2 (6%) 8 (6%)
Other 6 (18%) 16 (12%)
Unknown 2 (6%) 7 (5%)
Current smoker 7 (21%) 28 (21%) 1.0
Chronic lung disease 0 (0%) 19 (14%) 0.02
Coronary artery disease 11 (33%) 29 (22%) 0.2
Peripheral vascular disease 4 (12%) 18 (14%) 0.8
Cerebrovascular disease 3 (9%) 12 (9%) 1.0
First RRT 0.4
HD 19 (58%) 59 (45%)
PD 14 (42%) 71 (54%)
Kidney transplant 0 (0%) 2 (2%)
Dialysis era 0.2
1995–1997 15 (46%) 46 (35%)
1998–2000 9 (27%) 32 (24%)
2001–2003 9 (27%) 39 (30%)
2004–2007 0 (0%) 15 (11%)
Prescribed dialysate volume at baseline (l/week) 56 (56–63)a 56 (56–70)a 0.2
Weekly peritoneal Kt/V at baseline 2.14 (1.76–2.50)a 2.03 (1.69–2.47)a 0.7
Peritoneal transport status 0.4
High 0 (0%) 5 (4%)
High average 3 (9%) 22 (17%)
Low average 1 (3%) 7 (5%)
Low 2 (6%) 3 (2%)
Unknown/not specified 27 (82%) 95 (72%)
Centre size (no. of PD patients) 0.9
Small (p10) 0 (0%) 2 (2%)
Small-Med (11–38) 3 (9%) 11 (8%)
Med-Large (39–98) 5 (15%) 21 (17%)
Large (X99) 25 (76%) 98 (74%)
State 0.9
New South Wales 10 (30%) 40 (30%)
Northern Territory 0 (0%) 2 (2%)
Queensland 2 (6%) 18 (14%)
South Australia 1 (3%) 2 (2%)
Tasmania 0 (0%) 1 (1%)
Table 3 continued on the following page
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survival of 14 months (range 0–119 months), whereas Brown
et al.11 observed a mortality rate of 42% at 1 year after EPS
diagnosis with a median survival of 180 days (range 1–1075 days).
In contrast, the 1-year survival in our study was 69% with a
median survival of 4.0 years (95% CI 1.8–6.3 years). The apparent
disparity in results may be explained by the longer follow-up
period and possibly earlier detection of EPS in our study. The
median time from commencement of PD to EPS diagnosis was
shorter in our study (4.5 years) compared with either the Pan-
Thames study (7.0 years)21 or the Scottish Renal Registry study
(5.1 years).11 Moreover, the proportion of EPS cases detected
while patients were still on PD was also considerably higher in
our investigation (79 versus 41 and 26%, respectively). These
findings raise the possibility that early detection of EPS and early
transfer to hemodialysis may be associated with considerably
improved survival. It is also possible that treatment differences
accounted for survival differences between the ANZDATA and
United Kingdom studies, although this is difficult to address as
the ANZDATA Registry does not collect information on EPS
treatment.
The strengths of this study included its very large sample
size and inclusiveness. We included all patients receiving PD
in Australia and New Zealand during the study period,
thereby greatly enhancing the external validity of our findings
and facilitating the comparison of EPS cases and controls.
Moreover, our cohort consisted solely of incident patients,
thereby avoiding the potentially confounding factor of
survivor bias associated with prevalent population studies.
The time span of the cohort was contemporaneous, which
was of particular relevance as PD selection criteria and
practices may have changed over time. The findings were
robust across different statistical methodologies.
Table 3 | Continued
Characteristic EPS cases (n=33) Controls (n=132) P-value
Victoria 6 (18%) 20 (15%)
Western Australia 2 (6%) 11 (8%)
Peritonitis (episodes/patient-year on PD) 0.8 (0.4–1.2)a 0.7 (0.3–1.1)a 0.2
Renal transplantation 3 (10%) 25 (19%) 0.3
Total follow-up time (years) 6.7 (4.2–10.3)a 5.8 (3.7–7.5)a 0.1
Abbreviations: ATSI, Aboriginal and Torres Strait Islander; BMI, body mass index; eGFR, estimated glomerular filtration rate; EPS, encapsulating peritoneal sclerosis; ESRF, end-
stage renal failure; HD, hemodialysis; MPI, Maori and Pacific Islander; RRT, renal replacement therapy.
aInterquartile range.
Four controls were matched with each case for age, gender, diabetes mellitus, and time spent on PD.
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Figure 3 |Kaplan–Meier survival curves for encapsulating peritoneal sclerosis (EPS) cases (n¼ 33) compared with matched controls
(n¼ 132). Four controls were matched with each case for age, gender, diabetes mellitus, and time spent on peritoneal dialysis (PD).
Survival was timed from the commencement of PD. Data were only censored for end of study (31 December 2007). The difference between
the groups was not statistically significant (log rank score 0.004, P¼ 0.9).
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These strengths should be balanced against the study’s
limitations, which included limited depth of data collection.
ANZDATA does not collect important information, such as
laboratory investigations (including peritoneal equilibration
tests for patients starting PD in the 1990s), severity of
comorbidities, individual unit management protocols
(including antiseptic usage), PD prescription, dialysate compo-
sition, detailed peritonitis information (including dates and
microbiology), prescribed medication, and specific EPS
treatment. Although we adjusted for a large number of
patient characteristics, the possibility of residual confounding
could not be excluded. Although the PD cohort was one of
the largest among the published EPS studies, the number of
EPS cases (n¼ 33) was relatively small, such that the attempt
to identify independent predictors may have been limited by
inadequate statistical power. In common with other Regis-
tries, ANZDATA is a voluntary Registry and there is no
external audit of data accuracy, including the diagnosis of
EPS and the attribution of death to EPS. Consequently, the
possibilities of coding/classification bias, under-reporting,
and under-recognition of EPS cannot be excluded.
In conclusion, EPS is a rare condition affecting 0.4% of
PD patients after a median period on PD of 4.5 years. It is
independently predicted by younger age (especially o50
years) and longer time on PD (especially 44 years). In our
study of patients who were transferred to hemodialysis before
or immediately after EPS diagnosis, the median survival was
4 years and was not significantly different from that of PD
controls matched for age, gender, presence or absence of
diabetes mellitus, and time spent on PD. As emphasized in
the International Society for PD Guidelines,20 there is still
insufficient evidence to support a single rule about optimal
length of time on PD to avoid the risk of EPS and such
decisions should be tailored to the individual patient, based
on their age, prognosis, quality of life, potential risks of
hemodialysis, and suitability for renal transplantation.
MATERIALS AND METHODS
Study population
A previous ANZDATA Registry analysis examined the incidence and
predictors of EPS in both incident and prevalent Australian PD
patients between 1980 and 1994.16 The present study included all
end-stage kidney disease patients in Australia and New Zealand who
commenced PD between 1 January 1995 and 31 December 2007.
Follow-up continued until 31 December 2007. Ethical approval for
the use of registry data was obtained from human research ethics
committee of the Princess Alexandra Hospital. The data collected
included demographic data, cause of primary renal disease,
comorbidities at the start of dialysis (coronary artery disease,
peripheral vascular disease, cerebrovascular disease, chronic lung
disease, diabetes, hypertension, and smoking status), body mass
index, late referral (defined as commencement of dialysis within
3 months of referral to a nephrologists), peritonitis episodes, baseline
prescribed dialysate volume, state of residence, and treating center
size. Center size was categorized according to quartiles of the
numbers of patients cared for by individual units over the duration
of the study: small (o10 patients), small–medium (10–54 patients),
medium–large (55–134 patients), and large (4134 patients). Dialysis
era was categorized according to the date of PD commencement
(1995–1997, 1998–2000, 2001–2003, and 2004–2007). In a contem-
porary subgroup of patients, additional data were available for
estimated glomerular filtration rate48 at dialysis commencement,
baseline (within 6 months) peritoneal Kt/V, and baseline (within 6
months) dialysate:plasma creatinine ratio.
The diagnosis of EPS was made by nephrologists from each of the
contributing centers based on clinical, radiological, and pathological
criteria outlined by Rigby and Hawley.16 Patients were included if
there was small bowel obstruction with either surgical evidence of
EPS (characteristic macroscopic appearance of tanned or thickened
peritoneum) or radiological evidence of EPS (peritoneal calcifica-
tion, bowel thickening, bowel tethering, and bowel dilatation) in the
absence of other causes of bowel obstruction.
The primary outcomes examined were EPS development, time to
EPS diagnosis, and patient survival.
Statistical analysis
Results were expressed as frequencies and percentages for categorical
variables, mean±s.d. for normally distributed continuous variables,
and median and interquartile range for non-normally distributed
continuous data. Differences between patients with and without EPS
were analyzed using chi-square test for categorical data, unpaired t-test
for continuous normally distributed data, and Mann–Whitney test for
continuous non-normally distributed data. The independent pre-
dictors of EPS were evaluated by multivariate binary logistic regression
using backward stepwise elimination based on the likelihood ratio to
determine the most parsimonious model. Overall patient survival
curves, cumulative hazard plots, survival probabilities, and estimated
mean survival times were generated according to the Kaplan–Meier
method. Differences in the survival curves between two groups were
evaluated using the log rank test. Technique survival was censored for
renal transplantation, recovery of dialysis-independent renal function,
and end of study (31 December 2007). Time to EPS was defined as the
number of years spent on PD before the diagnosis of EPS. If the
diagnosis of EPS occurred after a patient transferred from PD to
hemodialysis, the time to EPS development was taken as the total time
spent on PD. Overall patient survival was taken as the time from PD
commencement until death. Data were censored for spontaneous
recovery of renal function and end of study. A matched case–control
analysis was also performed in which four control PD patients were
matched with each EPS case for age (within 5 years), gender, diabetes
mellitus, and time spent on PD (within 0.4 years). Patients were
followed from the commencement of PD until either death or the
end of study, at which point data were censored. Data were analyzed
using the software package SPSS for Windows release 16.0 (SPSS,
North Sydney, Australia). The P-values of o0.05 were considered
statistically significant.
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